8-K: TuHURA Biosciences Secures $3M Bridge Loan, Pledges IP

TuHURA Biosciences secures a $3M bridge loan from Matthew Nachtrab Revocable Trust, pledging ImmuneFx™ patents.

Summary

• TuHURA Biosciences, Inc. entered into a Secured Promissory Note and Loan Agreement with the Matthew Nachtrab Revocable Trust dated 12/18/2014 on October 27, 2025.
• The agreement provides for loans up to an aggregate principal amount of $3,000,000 during a 30-day availability period.
• An initial advance of $1,500,000 was made simultaneously with the agreement's execution, with an option for an additional $1,500,000 upon advance notice.
• The loans are designated for working capital purposes.
• The outstanding principal and accrued interest are due on the earlier of December 31, 2025, or 30 days following the successful closing of an equity financing exceeding $12,000,000 in gross cash proceeds.
• The loans bear an interest rate of 3% per month, payable in arrears on the maturity date.
• The company may prepay all or a portion of the loan without a prepayment fee.
• A loan fee of $150,000 is payable to the Lender on the maturity date.
• The loan is secured by a first priority perfected security interest in U.S. patents owned by the company related to its ImmuneFx™ technology platform.
• In connection with each loan advance, the company will issue Lender Warrants to purchase common stock, equal to 10% of the applicable loan advance divided by the Nasdaq Official Closing Price on the issuance date.
• An initial Lender Warrant was issued to purchase up to 65,217 shares of common stock.
• Each Lender Warrant is immediately exercisable and expires two years from its issuance date.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the high cost of capital (3% monthly interest, $150,000 fee), significant shareholder dilution from warrants, and the pledging of core intellectual property as collateral, all of which suggest financial distress or limited financing alternatives for the company.

Positives

• Secured up to $3,000,000 in bridge financing, providing immediate working capital for operations.
• The company retains flexibility to prepay the loan in whole or in part at any time without incurring a prepayment fee.
• The availability period allows for additional funding up to $1,500,000 if needed within 30 days.

Negatives

• The interest rate of 3% per month (equivalent to 36% per annum) is exceptionally high, indicating significant cost of capital.
• A substantial loan fee of $150,000 is payable on the maturity date, further increasing the cost of financing.
• The company's U.S. patents related to its core ImmuneFx™ technology platform are pledged as collateral, representing a significant asset at risk.
• The short maturity period (by December 31, 2025, or 30 days post-$12M+ equity raise) creates pressure for rapid repayment or securing substantial follow-on financing.
• The issuance of Lender Warrants, representing 10% of each loan advance's value, will result in dilution for existing shareholders upon exercise.

Risks

• Risk of default if the company fails to repay the loan by the maturity date or secure the required equity financing.
• Loss of the company's core ImmuneFx™ technology patents if an event of default occurs and the lender enforces its security interest.
• Significant shareholder dilution from the exercise of Lender Warrants, potentially impacting stock price and ownership percentages.
• The need to raise over $12,000,000 in equity financing to trigger an earlier maturity date, which may be challenging given market conditions.
• Potential for further financial strain if additional capital is not secured on more favorable terms before the loan matures.

Future Outlook

The company intends to use the loan proceeds for working capital and anticipates seeking a larger equity financing round exceeding $12,000,000, which would trigger an earlier repayment of this bridge loan.

Management Comments

• James A. Bianco, M.D., Chief Executive Officer, signed the Secured Promissory Note and Loan Agreement.
• Dan Dearborn, Chief Financial Officer, signed the Form 8-K.

Industry Context

Biotechnology companies, particularly those in development stages like TuHURA Biosciences, frequently rely on external financing to fund research, clinical trials, and operational expenses. Bridge loans are a common mechanism to secure short-term capital while larger, more strategic funding rounds (like equity financing) are being pursued. However, the terms of this loan, including the high interest rate and collateral, suggest a challenging funding environment or a perceived higher risk associated with the company compared to industry averages for less distressed financing.

Comparison to Industry Standards

• The 3% monthly interest rate (36% annually) is significantly higher than typical commercial bank loans or even many venture debt facilities, which usually range from single digits to mid-teens percentage points, indicating a high-risk profile or limited alternative financing options for TuHURA Biosciences.
• Pledging core intellectual property, such as the ImmuneFx™ technology patents, as first-priority collateral is a substantial concession, often seen in situations where a company's financial position is under considerable stress or when other assets are insufficient.
• The issuance of warrants representing 10% of the loan advance value is a common feature in bridge financing or venture debt, but combined with the high interest rate and IP collateral, it underscores the lender's demand for significant upside potential and risk mitigation.
• The short maturity period of approximately two months (or 30 days post-equity raise) is typical for bridge loans, but the reliance on a substantial $12M+ equity raise for early repayment highlights the urgency of the company's long-term financing needs, which is a common challenge for early-stage biotech firms.

Legal Proceedings

• The company represents that no actions, suits, proceedings, or investigations are pending or threatened in writing that seek to enjoin the execution, delivery, or performance of this Note or the transactions contemplated thereby, or that would reasonably be expected to result in liabilities in excess of $250,000.

Stakeholder Impact

• Shareholders face potential dilution from the issuance and exercise of Lender Warrants.
• The Matthew Nachtrab Revocable Trust (Lender) gains a first-priority security interest in the company's ImmuneFx™ patents, enhancing its creditor position.
• The provision of working capital supports the company's ongoing operations, potentially benefiting employees and suppliers.
• The company's ability to secure future equity financing will be critical for all stakeholders, as the bridge loan's terms are demanding.

Next Steps

• The company may draw an additional $1,500,000 under the loan agreement within the 30-day availability period.
• The company needs to secure an equity financing round exceeding $12,000,000 to trigger an earlier repayment of the bridge loan.
• The company must repay the outstanding principal and accrued interest by December 31, 2025, or 30 days after the qualifying equity financing.

Key Dates

Recommendation

The terms of this bridge loan, including a 3% monthly interest rate, a substantial loan fee, significant warrant-based dilution, and the pledging of core intellectual property, indicate a company under considerable financial pressure. While securing working capital is essential, the highly unfavorable terms suggest a challenging financial outlook and a high-risk investment profile, warranting a 'sell' recommendation for seasoned investors.

Keywords

Bridge Loan, Secured Promissory Note, Working Capital, Biotechnology, ImmuneFx, Patents, Warrants, Equity Financing, SEC Filing, Corporate Finance